[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 36 of about 36
31. Jones CM, Dickinson TM, Salvado A: Phase II open label trial of imatinib in polycythemia rubra vera. Int J Hematol; 2008 Dec;88(5):489-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Polycythemia rubra vera is a chronic myeloproliferative disorder characterized by panmyelosis with the resultant potential for thrombosis, myelofibrosis, and acute leukemia.
  • Patients meeting the Polycythemia Vera Study group criteria for the diagnosis of polycythemia vera, either naïve or intolerant to prior treatment were allowed to enroll.

  • Genetic Alliance. consumer health - Polycythemia vera.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Hematol. 2007 Jun;35(6):931-8 [17533047.001]
  • [Cites] Hematology. 2000;4(5):381-395 [11399580.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):387-97 [15837627.001]
  • [Cites] J Biol Chem. 1997 Mar 14;272(11):6850-3 [9054369.001]
  • [Cites] Blood. 1997 May 15;89(10):3574-81 [9160662.001]
  • [Cites] Blood. 1997 Nov 1;90(9):3370-7 [9345019.001]
  • [Cites] Semin Hematol. 1986 Apr;23(2):132-43 [3704665.001]
  • [Cites] Br J Haematol. 1994 Nov;88(3):497-505 [7529530.001]
  • [Cites] Am J Med Sci. 2003 Mar;325(3):149-52 [12640290.001]
  • [Cites] J Biol Chem. 2005 Jun 17;280(24):22788-92 [15863514.001]
  • [Cites] Am J Hematol. 1984;17(4):329-34 [6496458.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1710-4 [1371882.001]
  • [Cites] Exp Hematol. 2007 Jan;35(1):32-8 [17198871.001]
  • [Cites] Ann Intern Med. 2006 Feb 21;144(4):257-61 [16490911.001]
  • [Cites] Leukemia. 2003 Jun;17(6):1186-7 [12764388.001]
  • [Cites] Biochem J. 1997 Oct 1;327 ( Pt 1):73-80 [9355737.001]
  • [Cites] Int J Hematol. 1992 Apr;55(2):111-5 [1511160.001]
  • [Cites] Lancet. 2005 Mar 19-25;365(9464):1054-61 [15781101.001]
  • [Cites] Br J Haematol. 1994 Jan;86(1):12-21 [7516694.001]
  • [Cites] Nature. 2005 Apr 28;434(7037):1144-8 [15793561.001]
  • [Cites] Transfusion. 2003 Oct;43(10):1366-73 [14507266.001]
  • [Cites] Blood. 2003 Sep 15;102(6):2240-2 [12763928.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Jul 5;791(1-2):39-44 [12798163.001]
  • [Cites] Leukemia. 1994 Apr;8(4):631-7 [7512174.001]
  • (PMID = 19009241.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


32. Kawagoe H, Grosveld GC: Conditional MN1-TEL knock-in mice develop acute myeloid leukemia in conjunction with overexpression of HOXA9. Blood; 2005 Dec 15;106(13):4269-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conditional MN1-TEL knock-in mice develop acute myeloid leukemia in conjunction with overexpression of HOXA9.
  • Coexpression of MN1-TEL and IL-3, but not SCF, rapidly caused a fatal myeloproliferative disease rather than acute myeloid leukemia (AML).
  • Thus, the leukemogenic effect of MN1-TEL in our knock-in mice is pleiotropic, and the type of secondary mutation determines disease outcome.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • National BioResource Project. culture/stock collections - NBRP resources .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Leukoc Biol. 1999 Feb;65(2):217-31 [10088605.001]
  • [Cites] Semin Hematol. 1999 Oct;36(4 Suppl 7):59-72 [10595755.001]
  • [Cites] Oncogene. 2000 Feb 3;19(5):608-16 [10698505.001]
  • [Cites] Mol Cell Biol. 2000 May;20(9):3274-85 [10757811.001]
  • [Cites] Int J Hematol. 2000 Jun;71(4):301-8 [10905048.001]
  • [Cites] Mol Cell Biol. 2000 Dec;20(24):9281-93 [11094079.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Feb;23(2):122-5 [11216704.001]
  • [Cites] Exp Hematol. 2001 Jul;29(7):856-63 [11438208.001]
  • [Cites] Leukemia. 2002 Feb;16(2):186-95 [11840284.001]
  • [Cites] Blood. 2002 Jul 1;100(1):238-45 [12070033.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):63-74 [12086889.001]
  • [Cites] Int Immunol. 2002 Jul;14(7):813-22 [12096041.001]
  • [Cites] Oncogene. 2003 Feb 6;22(5):699-709 [12569362.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5428-37 [14500378.001]
  • [Cites] Mol Cell Biol. 2004 Feb;24(3):1256-69 [14729970.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2522-9 [14630789.001]
  • [Cites] Biotechnol Bioeng. 2004 Apr 20;86(2):174-87 [15052637.001]
  • [Cites] Haematologica. 2004 Aug;89(8):920-5 [15339674.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6091-100 [15342392.001]
  • [Cites] Genes Dev. 2004 Oct 1;18(19):2336-41 [15371326.001]
  • [Cites] EMBO J. 1989 Jan;8(1):133-6 [2653809.001]
  • [Cites] Blood. 1991 Dec 1;78(11):3012-20 [1954386.001]
  • [Cites] Hematol Oncol Clin North Am. 1992 Jun;6(3):571-86 [1613007.001]
  • [Cites] EMBO J. 1993 Oct;12(10):3835-46 [8104786.001]
  • [Cites] Leuk Lymphoma. 1993 Oct;11(3-4):197-205 [8260894.001]
  • [Cites] Cell. 1994 Apr 22;77(2):307-16 [8168137.001]
  • [Cites] Oncogene. 1995 Apr 20;10(8):1511-9 [7731705.001]
  • [Cites] Oncogene. 1995 Apr 20;10(8):1521-8 [7731706.001]
  • [Cites] Br J Haematol. 1995 Mar;89(3):516-26 [7734349.001]
  • [Cites] Science. 1995 Sep 8;269(5229):1427-9 [7660125.001]
  • [Cites] Nat Genet. 1996 Feb;12(2):149-53 [8563752.001]
  • [Cites] Nat Genet. 1996 Feb;12(2):159-67 [8563754.001]
  • [Cites] Blood. 1996 Jun 1;87(11):4804-8 [8639852.001]
  • [Cites] J Immunol Methods. 1996 Oct 16;197(1-2):139-50 [8890901.001]
  • [Cites] Int J Biochem Cell Biol. 1997 Dec;29(12):1371-87 [9570133.001]
  • [Cites] EMBO J. 1998 Jul 1;17(13):3714-25 [9649441.001]
  • [Cites] Genes Dev. 1998 Aug 15;12(16):2475-87 [9716401.001]
  • [Cites] Leukemia. 1999 Jan;13(1):6-13 [10049061.001]
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4278-86 [16081688.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12804-9 [10536003.001]
  • [Cites] Blood. 1999 Sep 1;94(5):1761-72 [10477702.001]
  • (PMID = 16105979.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA217G; United States / NCI NIH HHS / CA / CA72999-07
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / ETS translocation variant 6 protein; 0 / Homeodomain Proteins; 0 / Mn1 protein, mouse; 0 / Oncogene Proteins; 0 / Proto-Oncogene Proteins c-ets; 0 / Proto-Oncogene Proteins c-myc; 0 / Repressor Proteins; 0 / homeobox protein HOXA9
  • [Other-IDs] NLM/ PMC1895240
  •  go-up   go-down


33. Finazzi G, Barbui T: Expertise-based management in essential thrombocythemia and polycythemia vera. Cancer J; 2007 Nov-Dec;13(6):372-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The clinical courses of polycythemia vera (PV) and essential thrombocythemia (ET) are characterized by an increased incidence of thrombotic and hemorrhagic complications and an inherent tendency to progress into myelofibrosis or acute myeloid leukemia.
  • Interferon-alpha (IFN-alpha) or anagrelide could be considered in selected young patients or as second-line therapy in those intolerant of hydroxyurea or with refractory disease.


3
Advertisement
4. Kar B, Nandhini B, Revathi R: Ring chromosome 8 and trisomy 8 in a patient with acute myeloid leukemia. Indian J Hematol Blood Transfus; 2009 Mar;25(1):30-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ring chromosome 8 and trisomy 8 in a patient with acute myeloid leukemia.
  • We describe a child with Acute Myeloid Leukemia (AML M7) with trisomy 8 and ring chromosome 8.
  • This 15-month-old girl had presented with a history of fever, weight loss of 1 kg, gum bleeds and pallor.
  • Clinical examinations revealed no nodes or organomegaly.
  • She developed acute myelofibrosis soon after the second cycle of chemotherapy with swinging fever and rapidly enlarging spleen.
  • She passed away on day 11 post transplantation of veno-occlusive disease of liver and multiorgan failure.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematol Pathol. 1992;6(3):161-7 [1429344.001]
  • [Cites] Cancer Genet Cytogenet. 1992 May;60(1):53-9 [1591707.001]
  • [Cites] Cancer Genet Cytogenet. 1991 Nov;57(1):79-85 [1756488.001]
  • [Cites] Am J Hematol. 1997 Dec;56(4):224-9 [9395183.001]
  • [Cites] Leukemia. 1996 Dec;10(12):1883-90 [8946926.001]
  • [Cites] Cancer Genet Cytogenet. 1994 Dec;78(2):181-8 [7828151.001]
  • [Cites] Eur J Haematol. 1988 Oct;41(4):341-6 [3197821.001]
  • (PMID = 23100969.001).
  • [ISSN] 0971-4502
  • [Journal-full-title] Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
  • [ISO-abbreviation] Indian J Hematol Blood Transfus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3453485
  • [Keywords] NOTNLM ; Acute myeloid leukemia / Ring chromosome 8 / Trisomy 8
  •  go-up   go-down


35. Kreft A, Springer E, Lipka DB, Kirkpatrick CJ: Wild-type JAK2 secondary acute erythroleukemia developing after JAK2-V617F-mutated primary myelofibrosis. Acta Haematol; 2009;122(1):36-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wild-type JAK2 secondary acute erythroleukemia developing after JAK2-V617F-mutated primary myelofibrosis.
  • A 54-year-old female patient developed acute erythroleukemia after an 8-year course of primary myelofibrosis.
  • A bone marrow trephine biopsy disclosed 2 morphologically distinct areas of chronic primary myelofibrosis and acute erythroleukemia.
  • Although the activating JAK2-V617F mutation was not maintained in blasts of acute erythroleukemia, it was detectable in the chronic phase of primary myelofibrosis, indicating that this mutation did not play a role in the leukemic transformation of erythroid cells.
  • [MeSH-major] Janus Kinase 2 / genetics. Leukemia, Erythroblastic, Acute / genetics. Primary Myelofibrosis / complications. Primary Myelofibrosis / genetics

  • Genetic Alliance. consumer health - Acute Erythroleukemia.
  • Genetic Alliance. consumer health - Myelofibrosis.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 S. Karger AG, Basel
  • (PMID = 19713696.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


36. Saint-Martin C, Leroy G, Delhommeau F, Panelatti G, Dupont S, James C, Plo I, Bordessoule D, Chomienne C, Delannoy A, Devidas A, Gardembas-Pain M, Isnard F, Plumelle Y, Bernard O, Vainchenker W, Najman A, Bellanné-Chantelot C, French Group of Familial Myeloproliferative Disorders: Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms. Blood; 2009 Aug 20;114(8):1628-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms.
  • The JAK2(V617F) mutation does not elucidate the phenotypic variability observed in myeloproliferative neoplasm (MPN) families.
  • In a patient with 2 TET2 mutations, the analysis of 5 blood samples at different phases of her disease showed the sequential occurrence of JAK2(V617F) and TET2 mutations concomitantly to the disease evolution.
  • TET2 mutations were mainly observed (10 of 12) in patients with primary myelofibrosis or patients with polycythemia vera or essential thrombocythemia who secondarily evolved toward myelofibrosis or acute myeloid leukemia.
  • [MeSH-major] Bone Marrow Neoplasms / genetics. DNA-Binding Proteins / genetics. Myeloproliferative Disorders / genetics. Proto-Oncogene Proteins / genetics
  • [MeSH-minor] Adult. Aged. Cells, Cultured. DNA Mutational Analysis. Family. Female. Genetic Predisposition to Disease. Humans. Male. Middle Aged. Pedigree. Phenotype






Advertisement